Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 6.40M | 7.55M | 5.32M | 4.24M | 1.53M | 1.02M |
Gross Profit | 3.58M | 4.80M | 3.69M | 3.06M | 832.52K | 299.88K |
EBITDA | -11.77M | -13.43M | -11.68M | -9.93M | -11.52M | -11.67M |
Net Income | -8.57M | -8.57M | -7.18M | -6.25M | -9.11M | -9.04M |
Balance Sheet | ||||||
Total Assets | 35.24M | 35.24M | 26.62M | 29.61M | 37.90M | 19.33M |
Cash, Cash Equivalents and Short-Term Investments | 28.62M | 28.62M | 20.61M | 24.82M | 11.02M | 16.33M |
Total Debt | 576.89K | 576.89K | 689.69K | 562.30K | 507.56K | 621.72K |
Total Liabilities | 20.67M | 20.67M | 22.08M | 23.46M | 27.99M | 2.46M |
Stockholders Equity | 14.57M | 14.57M | 4.53M | 6.15M | 9.90M | 16.87M |
Cash Flow | ||||||
Free Cash Flow | -8.94M | -9.04M | -7.45M | 13.96M | -6.80M | -4.82M |
Operating Cash Flow | -8.68M | -8.68M | -6.51M | 14.59M | -6.26M | -4.63M |
Investing Cash Flow | -359.06K | -359.06K | -942.02K | -631.56K | -535.02K | -188.52K |
Financing Cash Flow | 17.05M | 17.05M | 3.24M | -164.61K | 1.49M | 709.15K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
55 Neutral | 114.23M | -4.38 | 0.00% | ― | 0.00% | 0.66% | |
50 Neutral | 366.97M | -5.92 | 0.00% | ― | 0.00% | -19.21% | |
46 Neutral | 306.09M | -21.43 | 0.00% | ― | 1271.12% | 36.87% | |
45 Neutral | AU$280.78M | ― | -89.70% | ― | 42.05% | -0.84% | |
40 Underperform | 117.36M | -5.73 | 0.00% | ― | -20.79% | 73.98% | |
40 Underperform | 105.34M | -12.94 | 0.00% | ― | 700.00% | 26.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Orthocell Ltd has announced the use of its nerve repair device, Remplir, in nerve-sparing robotic-assisted radical prostatectomies (RARP) in Australia, aiming to reduce post-surgical complications such as erectile dysfunction and urinary incontinence. This development represents a significant opportunity for Orthocell to expand Remplir’s market presence, as the product is being adopted by urologists to protect and restore nerve function during prostate cancer surgeries, potentially increasing its global total addressable market.
The most recent analyst rating on (AU:OCC) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has announced that its 2025 Annual General Meeting will be held on November 6, 2025, with the re-election of directors as a key agenda item. The closing date for director nominations is September 18, 2025. This announcement is part of Orthocell’s ongoing efforts to strengthen its governance structure as it continues to expand its market presence globally, particularly in the US with its regenerative medicine products.
The most recent analyst rating on (AU:OCC) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced interim results from its Remplir Real World Evidence study, demonstrating an 81.1% overall treatment success rate in nerve repair procedures. The study supports the US sales rollout and regulatory submissions in the EU and UK, highlighting Remplir’s effectiveness in real-world settings. The data shows significant improvements in muscle recovery and symptom relief, with no reported complications, reinforcing Remplir’s clinical success and its adoption by over 200 surgeons in more than 165 hospitals.
The most recent analyst rating on (AU:OCC) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Limited has issued 1,500,000 fully paid ordinary shares following the exercise of unlisted options, allowing these shares to be traded immediately. This move is part of the company’s compliance with the Corporations Act, potentially enhancing its market operations and providing liquidity for stakeholders.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the issuance of 1,500,000 ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code OCC. This move is part of the company’s strategic efforts to enhance its capital structure, potentially strengthening its market position and providing additional resources for its ongoing projects in regenerative medicine.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the appointment of Mr. Michael McNulty as a director, effective from September 1, 2025. Mr. McNulty holds 2,000,000 unlisted options and 56,169 ordinary fully paid shares through McNulty Family Pty Ltd and his spouse, indicating a significant personal investment in the company. This appointment may enhance Orthocell’s strategic direction and strengthen its position in the regenerative medicine sector.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd announced the issuance of 2,000,000 unquoted options, set to expire on August 31, 2028, with an exercise price of $1.53. This issuance is part of a previously announced transaction and is not intended to be quoted on the ASX, potentially impacting the company’s capital structure and offering strategic flexibility in its financial operations.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
Orthocell Ltd has announced the appointment of Mr. Michael McNulty as a director, effective from September 1, 2025. Mr. McNulty holds 2,000,000 unlisted options through McNulty Family Pty Ltd, exercisable at $1.53 and expiring on August 31, 2028. This appointment is expected to strengthen the company’s leadership team, potentially impacting its strategic direction and stakeholder relations positively.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.